Johnson & Johnson, the healthcare and pharmaceutical company, reported lower than expected quarterly sales on Tuesday, hit by the loss of patents on one of its leading branded drugs and the impact of the strong dollar on international sales.

It also issued a forecast for its coming fiscal year that was below Wall Street’s expectations: $4.45-$4.55.